

Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

NEOADJUVANT

A022104/Janus Trial
(Triplet vs. double chemo)

Coord: A. Luna
Accrual: 1/5

EA2201
(Nivo + Ipi + radiation)

Coord: K. Ghio
Accrual: 0/3

UCI 21-67
(Epacadostat + short course
radiation + chemo)

Pending IRB, budget, contract

ADJUVANT

NRG-GI008/CIRCULATE
(ctDNA guided tx)

Coord: A. Luna
Accrual: 1/5

NRG-GI005/COBRA
(SOC vs mFOLFOX6 or CAPOX or
surveillance)

Coord: LM Aguilar
Accrual: 2/5

INTRA-OPERATIVE

UCI 20-163
(SOC vs CG-100 Intraluminal)

Coord: M. Nguyen
Bypass Device

MOLECULAR FAILURE

UCI 20-43
(TAS102 + irinotecan)

Coord: K. Ghio
Accrual: 2/11

1L METASTATIC

UCI 22-07
(BXQ-350 + mFOLFOX7
and bevacizumab)

Coord: A. Luna
Accrual: 2/5

UCI 21-110
(only EC naïve patients
with BRAFV600E CRC)
Encorafenib + cetuximab
+ ERAS-007

Coord: P. Yang
Accrual: 6/15

A022101
(at least 4 months of
chemo once metastatic
disease is confirmed)

Coord: A. Luna
Accrual: 0/2

2L METASTATIC

S2107
(Encorafenib + cetuximab +/- nivo)

Coord: LM Aguilar
Accrual: 0/3

UCI 21-208
(nti-DR5 targeting pentameric
lgm antibody IGM-8444)

Coord: M. Nguyen
Accrual: 4/8

UCI 22-87
(KRAS inhibitor)

Coord: LM Aguilar
Accrual: 6/20

UCI 22-131
(XL092 +
atezolizumab vs.
regorafenib)

Coord: P. Yang
Accrual: 4/7

UCI 21-39
(Pembro + TATE)

Coord: LM Agilar
Accrual: 17/30

UCI 20-84
(HES vs. SOC TACE)

Coord: M. Duron
Accrual: 8/13

UCI 23-101
(Nivo + BMS-986288 vs regorafenib)

Coord: P. Yang
Accrual: 0/10

Enrollment pause expected to re-open Q1/Q2 2024

Newly Diagnosed

ECOG-EA2182
(Mitomycin-C + 5-Fluorouracil +
Capecitabine)

Coord: J. Koff
Accrual: 1/3

Advanced/Metastatic

ECOG-EA2176
(Nivolumab + Carboplatin +
Paclitaxel)

Coord: J. Koff
Accrual: 3/5

Neoadjuvant

UCI 21-191
(SOC therapy with
ctDNA testing)

Coord: A. Luna
Pending activation

Newly Diagnosed Metastatic

UCI 20-87
(V Paclitaxel + IV 5-
FU + IV leucovorin +
IP paclitaxel)

Coord: L. Mejia
Accrual: 18/20

UCI 22-76
(Anti-PD-1 + chemo
+/- anti-TIGIT)

Coord: J. Koff
Accrual: 1/10

A022102
(mFOLFIRINOX +/-
Nivolumab vs.
FOLFOX +/-
Nivolumab)

Coord: J. Koff
Accrual: 0/7

UCI 21-193
(FGFR inhibitor +
mFOLFOX6 + antiPD-
L1 (nivolumab))

Coord: M. Nguyen
Accrual: 1/12

EA2183
(SOC + XRT)

Coord: J. Koff
Pending activation

Recurrent

UCI 23-78
(EGFR and MET-
directed antibody)

Coord: TBD
Pending activation

UCI 16-94
(Tirapazamine,
Nivolumab)

Coord: LM Aguilar
Accrual: 24/40

UCI 23-109
(Disitamab Vedotin +
Tucatinib)


Coord: TBD
Pending activation

UCI 22-51
(ASP2138)

Coord: TBD
Pending Activation

UCI 21-10
(Bispecific antibody (anti-CLDN18.2 + anti-
4-1BB))

Coord: K. Ghio
Accrual: 8/10



UCI 23-85
(BA3182 +
(EPCAM)/CD3
Antibody)

Coord: TBD
Accrual: 0/5

UCI 21-146
(Anti-Tissue Factor
monoclonal
antibody-
BCNvcMMAE
conjugate)

Coord: C. Kang
Accrual: 4/11

UCI 23-35
(BMS-986442 in
Combination with
Nivolumab or
Nivolumab and
Chemotherapies)

Coord: LM Aguilar
Accrual: 0/10

ETCTN-10579
(ZEN003694 (ZEN-
3694) +
capecitabine)

Coord: P. Yang
Accrual: 0/4

UCI 22-37
(Inhibitor of KDM4
histone
demethylase)

Coord: A. Luna
Accrual: 3/10

UCI 22-26
(Androgen and
glucocorticoid
receptor
antagonist)

Coord: N. Ferrand
Accrual: 6/12

UCI 22-221
BiTe of B7-H6
(Central B7-H6 testing)
HCC and Pancreatic
(also NSCLC, HNSCC,
CRC, and gastric)

Coord: P. Yang
Accrual: 2/12

UCI 03-03

(Immunologic response analysis)

Coord: S. Ninofranco
Accrual: 262/400

UCI 20-101

(Biospecimen Collection
for patients planned to
start treatment)

Coord: N. Arechiga
Accrual: 53/80

UCI 23-21

P(Exosome Gene
Expression Peritoneal
Fluid&Plasma in
Gastrointestinal
Malignancies)

Coord: LM Aguilar
Accrual: 0/70

UCI 20-04

(Tissue Collection)

Coord: S. Ninofranco
Accrual: 98/130

UCI 22-109

alonosteron buccal
film vs. IV Palonosetron)

Coord: P. Yang
Accrual: 1/30